{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:12:54Z","timestamp":1792732374027,"version":"4.5.0"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,6,27]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICI) have improved cancer outcomes but often cause immune-related adverse events, including granulomatous reactions (GRs). We analyzed GRs in patients receiving anticytotoxic T-lymphocyte\u2013associated protein 4 (anti-CTLA4), antiprogrammed cell death protein 1 (anti-PD1)\/antiprogrammed death ligand 1 (anti-PDL1), and anti-CTLA4\/anti-PD1 therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a literature review of GRs in patients receiving ICI. Data were extracted from 166 articles, including demographics, GR organ distribution, and pathological findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 261 patients, the mean age of GR onset was 59.3 (SD 13.0) years. The most common cancer types were melanoma (57%) and lung cancer (21%). Lymph nodes (52%) and skin (35%) were the predominantly affected organs; however, GRs also involved the liver, kidney, and bone. Granulomas were nonnecrotizing in 64% of cases and necrotizing in 15% of cases. Forty-five percent of patients were treated with systemic corticosteroids (CS), and 11% required a CS-sparing agent. Median follow-up time was 10.1 (IQR 4.0-22.2) months. Most GRs (64%) had resolved by last follow-up. Compared to those treated with combination ICI, patients treated with anti-PD1\/anti-PDL1 monotherapy were older and had a longer time to onset of GR. They were less likely to be treated with CS for GRs. In patients with melanoma, necrotizing GRs were more common with combination ICI. GRs in the lungs and lymph nodes were more likely to be nonnecrotizing, and GRs in the liver were more commonly necrotizing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GRs in patients with cancer treated with ICI can occur in many organ systems and were most commonly nonnecrotizing. Patients treated with combination ICI had more severe reactions. Most GRs resolved with CS treatment or ICI discontinuation. (PROSPERO ID: CRD42024501205)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0108","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:35:19Z","timestamp":1752586519000},"page":"1200-1206","source":"Crossref","is-referenced-by-count":5,"title":["Necrotizing and Nonnecrotizing Granulomatous Reactions in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Literature Review"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-9973","authenticated-orcid":false,"given":"Elizabeth Y.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genna","family":"Braverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-9309","authenticated-orcid":false,"given":"Nilasha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-379X","authenticated-orcid":false,"given":"Deanna P.","family":"Jannat-Khah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8619-8588","authenticated-orcid":false,"given":"Karmela K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8707-4859","authenticated-orcid":false,"given":"Bridget","family":"Jivanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-8351","authenticated-orcid":false,"given":"Anne R.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2025120106151105000_52.12.1200.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025120106151105000_52.12.1200.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025120106151105000_52.12.1200.3","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025120106151105000_52.12.1200.4","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaad.2018.07.051","article-title":"Immune checkpoint inhibitors and the development of granulomatous reactions","volume":"81","author":"Cornejo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025120106151105000_52.12.1200.5","doi-asserted-by":"crossref","first-page":"100626","DOI":"10.1016\/j.xkme.2023.100626","article-title":"Immune checkpoint inhibitor\u2013associated sarcoidosis reaction in the kidney: case report","volume":"5","author":"Charkviani","year":"2023","journal-title":"Kidney Med"},{"key":"2025120106151105000_52.12.1200.6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor\u2013associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025120106151105000_52.12.1200.7","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/cancers14122937","article-title":"Sarcoid-like granulomatosis associated with immune checkpoint inhibitors in melanoma","volume":"14","author":"Melin","year":"2022","journal-title":"Cancers"},{"key":"2025120106151105000_52.12.1200.8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10147-019-01490-2","article-title":"Immune checkpoint inhibitor-induced sarcoidosis-like granulomas","volume":"24","author":"Rambhia","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2025120106151105000_52.12.1200.9","unstructured":"U.S. Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. [Accessed July 11, 2025.] Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"},{"key":"2025120106151105000_52.12.1200.10","doi-asserted-by":"crossref","first-page":"102587","DOI":"10.1016\/j.autrev.2020.102587","article-title":"Sarcoidosis related to checkpoint and BRAF\/MEK inhibitors in melanoma","volume":"19","author":"Rubio-Rivas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025120106151105000_52.12.1200.11","doi-asserted-by":"crossref","first-page":"e14618","DOI":"10.1111\/dth.14618","article-title":"Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case","volume":"34","author":"Apalla","year":"2021","journal-title":"Dermatol Ther"},{"key":"2025120106151105000_52.12.1200.12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2021.07.015","article-title":"Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: a case\u2013control study","volume":"156","author":"Cabani\u00e9","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025120106151105000_52.12.1200.13","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41598-022-07770-8","article-title":"Anti-nuclear antibody and a granuloma could be biomarkers for iCIs-related hepatitis by anti-PD-1 treatment","volume":"12","author":"Kondo","year":"2022","journal-title":"Sci Rep"},{"key":"2025120106151105000_52.12.1200.14","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000301"},{"key":"2025120106151105000_52.12.1200.15","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.3390\/ijms22126474","article-title":"Granulomatous inflammation in anca-associated vasculitis","volume":"22","author":"M\u00fcller","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025120106151105000_52.12.1200.16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-100022"},{"key":"2025120106151105000_52.12.1200.17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2025120106151105000_52.12.1200.18","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-35"},{"key":"2025120106151105000_52.12.1200.19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903369"},{"key":"2025120106151105000_52.12.1200.20","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0037OC"},{"key":"2025120106151105000_52.12.1200.21","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1111\/jdv.14617","article-title":"Granuloma annulare associated with immune checkpoint inhibitors","volume":"32","author":"Wu","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025120106151105000_52.12.1200.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821218116"},{"key":"2025120106151105000_52.12.1200.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.7735"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:15:47Z","timestamp":1764598547000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.3899\/jrheum.2025-0108"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0108","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}